Unicocell Biomed Co., Ltd. (referred to as "UnicoCell", stock code: 6794) has been selected to deliver an oral presentation at the 2026 Annual Meeting of the International Society for Cell & Gene Therapy (ISCT), one of the most prestigious international scientific conferences in the field of cell and gene therapy. The ISCT 2026 Annual Meeting will be held from May 6 to 8, 2026, at The Convention Centre Dublin, Ireland, with more than 3,000 delegates from over 60 countries expected to attend, including clinicians, regulators, researchers, and industry professionals worldwide.
UnicoCell's clinical results will be presented on May 8, 2026, in the "Mesenchymal Stem/Stromal Cells" oral abstract session, under the title "Clinical Development of Allogeneic Adipose-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease: An Integrated Translational Evidence Framework." UnicoCell is the only Taiwan company selected for an oral presentation in the stem cell category at this year's meeting, representing a significant milestone for Taiwan's stem cell therapy research community on the international stage.
The presentation will report results from UnicoCell's Phase 1/2 clinical trial of ELIXCYTE®-CKD, benchmarked against real-world data. The findings demonstrate the potential of ELIXCYTE®-CKD to slow the decline in renal function and halt disease progression in patients with chronic kidney disease (CKD), with a particularly notable trend toward disease stabilization observed in high-risk patient populations. CKD affects an estimated more than 800 million patients worldwide and remains an area of significant unmet medical need, as no existing treatment can fundamentally alter disease course, making CKD one of the most actively pursued indications in global cell therapy research.
ELIXCYTE®-CKD was granted U.S. FDA Fast Track designation in March 2025, a status intended for therapies with the potential to address serious conditions with substantial unmet medical needs, supporting accelerated development and regulatory review of subsequent clinical programs. In parallel, UnicoCell continues to advance a mechanism of action (MOA)- and potency-anchored translational medicine framework to characterize the immunomodulatory and tissue repair properties of ELIXCYTE®. Research indicates that ELIXCYTE® may exert tissue-protective effects through modulation of the immune microenvironment, inhibition of pro-inflammatory macrophage polarization, and promotion of angiogenesis. The Company is also establishing key potency indicators linking product quality attributes to clinical outcomes, in preparation for international regulatory submissions.
Contact: Ray Liu
Phone: 886-2-27922699
Email: info@unicocell.com